Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Hypercholesterolemia Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Hypercholesterolemia. Eligibility criteria explained in plain English.

TrialFinderData lists 11 Hypercholesterolemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 25% (1 studies); the largest phase groups are Phase 3: 1, Phase 4: 1, Phase 2: 1, Phase 2 / Phase 3: 1.

Research is led by Stephen Nicholls (1), University of Valencia (1), Midwest Center for Metabolic and Cardiovascular Research (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Alirocumab (drug, 2 trials), followed by Early Intervention, Plant sterols 2g/day.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track Hypercholesterolemia trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05325034

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific

Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study. Patients will be recruited during hospitalisation and be...

Sponsor: Stephen NichollsEnrolling: 200020 locations
RECRUITINGNCT06481020

Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)

Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with...

Sponsor: University of ValenciaEnrolling: 421 location
RECRUITINGNCT07514663

Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile

The goal of this clinical trial is to assess the effects of corn and avocado oils as part of controlled feeding diets on the cardiometabolic risk factor profile in men and women...

Sponsor: Midwest Center for Metabolic and Cardiovascular ResearchEnrolling: 541 location
RECRUITINGPhase 3NCT03480568

Alirocumab in Patients on a Stable Dialysis Regimen

12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9...

Sponsor: Baylor Research InstituteEnrolling: 201 location
RECRUITINGNCT07295327

Effect of Two Food Supplements on Lipid Profile in Patients With Mild Hypercholesterolemia

The primary outcome is to evaluate the effect of Cynacol on the change in LDL-C levels compared to Metacol after 90 days of supplementation. The secondary outcomes are to...

Sponsor: Fondazione IRCCS Policlinico San Matteo di PaviaEnrolling: 401 location
RECRUITINGNCT05430828

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy

Evaluation of adherence, persistence and efficacy of treatment with PCSK9 inhibitors in a real-life Italian population.

Sponsor: Federico II UniversityEnrolling: 500020 locations
RECRUITINGNCT07524101

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination...

Sponsor: Yonsei UniversityEnrolling: 19521 location
RECRUITINGPhase 4NCT07581808

Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention

This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk...

Sponsor: University Medical Centre LjubljanaEnrolling: 601 location
RECRUITINGNCT00353782

Causes and Natural History of Dyslipidemias

This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the...

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)Enrolling: 20001 location
RECRUITINGPhase 2NCT07477704

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have...

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of...

Sponsor: Regeneron PharmaceuticalsEnrolling: 4206 locations
RECRUITINGPhase 2 / Phase 3NCT07404553

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9...

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors....

Sponsor: Beijing Suncadia Pharmaceuticals Co., LtdEnrolling: 1261 location

Frequently Asked Questions

There are currently 11 clinical trials for Hypercholesterolemia, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Hypercholesterolemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Hypercholesterolemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.